Comments

Entrada Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Entrada Therapeutics (TRDA) operate in?

Entrada Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

TRDANASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$11.33

-0.61-5.11%

At close: -

$11.33

0.000.00%

After Hours: 4:00 PM EDT

Q4 2024 Earnings were released on Thu Feb 27th, before the market open

Entrada Therapeutics (TRDA) Forecast

News Earnings Entrada Therapeutics (TRDA) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Entrada Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TRDA | Benzinga

Explore Entrada Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TRDA.

Open	$11.95
Close	$11.33
Volume / Avg.	456.44K / 118.67K
Day Range	$11.28 - $12.05
52 Wk Range	11.35 - 21.79
Market Cap	$425.95M
P/E Ratio	7.12
Dividend Yield	-
Exchange	NASDAQ
RSI	29
Short Interest	6.45%
Days to Cover	15.08

Recent News

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.

Vandana Singh

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

Zacks

Evotec Rises 12% on $75M Milestone Payment From BMY

Evotec (NASDAQ: EVO) achieved substantial progress in its strategic partnership with Bristol Myers Squibb (NYSE: BMY) relating to building a molecular glue-based pipeline.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$11.95
Close	$11.33
Volume / Avg.	456.44K / 118.67K
Day Range	$11.28 - $12.05
52 Wk Range	11.35 - 21.79
Market Cap	$425.95M
P/E Ratio	7.12
Dividend Yield	-
Exchange	NASDAQ
RSI	29
Short Interest	6.45%
Days to Cover	15.08

About Entrada Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of p...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Entrada Therapeutics (TRDA) stock?

You can purchase shares of Entrada Therapeutics (NASDAQ:TRDA) through any online brokerage.

View our list of the best stock brokerages

Who are Entrada Therapeutics (TRDA) competitors?

Other companies in Entrada Therapeutics’s space includes: Tectonic Therapeutic (NASDAQ:TECX), Humacyte (NASDAQ:HUMA), Precigen (NASDAQ:PGEN), Upstream Bio (NASDAQ:UPB) and Altimmune (NASDAQ:ALT).

What is the forecast, or price target, for Entrada Therapeutics (TRDA) stock?

Entrada Therapeutics has a consensus price target of $23.40.

What is the current price for Entrada Therapeutics (TRDA)?

The stock price for Entrada Therapeutics (NASDAQ: TRDA) is $11.33 last updated March 3, 2025 at 4:00 PM EST.

Does Entrada Therapeutics (TRDA) pay a dividend?

There are no upcoming dividends for Entrada Therapeutics.

When is Entrada Therapeutics (NASDAQ:TRDA) reporting earnings?

Entrada Therapeutics’s Q1 earnings are confirmed for Tuesday, May 6, 2025.

Is Entrada Therapeutics (TRDA) going to split?

There is no upcoming split for Entrada Therapeutics.

What sector and industry does Entrada Therapeutics (TRDA) operate in?

Entrada Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.